

Original Article

COMPARISON OF PAIN SCORE IN OSTEOARTHRITIS PATIENTS TREATED WITH A COMBINATION OF DIACEREIN AND MELOXICAM AND MELOXICAM ALONE

NI MADE OKA DWICANDRA^{a*}, ANTONIOUS ADJI PRAYITNO SETIADI^b

^aPharmacy Department, Institute of Health Sciences Medika Persada Bali, Denpasar, Bali, Indonesia, ^bDepartement of Clinical Pharmacy, Pharmacy Faculty, University of Surabaya, Surabaya, Jawa Timur, Indonesia
Email: okadwicandra@gmail.com

Received: 12 Feb 2017 Revised and Accepted: 20 Apr 2017

ABSTRACT

Objective: Osteoarthritis (OA) is a progressive chronic disease with the loss of articular cartilage. In managing OA, inadequate pain relief (IPR) often occurs, particularly with a single non steroidal anti-inflammatory drugs (NSAIDs) therapy. In this research, pain outcome of OA patients treated with a combination of diacerein and meloxicam vs meloxicam alone was evaluated.

Methods: This research was conducted at rumah sakit umum daerah (RSUD) Dr. Mohammad Soewandhie Surabaya by using randomized controlled trial (RCT) design. Pain outcome was evaluated by pain intensity and area under the curve (AUC) of pain score in week 0-4th.

Results: There were a significantly different ($p < 0.05$) in pain intensity seen in 3rd and 4th weeks after treated with a combination of diacerein and meloxicam, and with meloxicam only. However, there were no different in AUC pain score between combination and single therapy.

Conclusion: Combination therapy of diacerein and meloxicam was more effective than meloxicam alone. A significant effect of a combination therapy of diacerein and meloxicam occurred at 3rd weeks. The prolong study in order to get the differences in AUC pain score are needed.

Keywords: Osteoarthritis, Diacerein, Meloxicam, Pain intensity

© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>)
DOI: <http://dx.doi.org/10.22159/ijpps.2017v9i6.17671>

INTRODUCTION

Osteoarthritis (OA) is a progressive chronic disease that was characterized by loss of articular cartilage [1]. World Health Organization data showed that OA is still one of the ten most diseases that caused disability in developed countries. Prevalence of radiological knee OA in Indonesia was 15.5% in men and 12.7% in women between 40-60 y of age [2].

Osteoarthritic pain is a chronic pain. Its remission for longer period is difficult [3]. Osteoarthritis and pain symptom experienced by patients have bad effects. Walking limitations have an impact on activities of daily living, which 11% of patients need assistance to do personal care [1]. Osteoarthritis patients also have limitations to work [4]. A disability that occurs in OA patients is associated with greater depression [5]. However, in its management, inadequate pain relief (IPR) was occurred in 54-64% of patients. Satisfaction and quality of life become worse because of IPR [6-8].

Among the study of OA therapy, non steroidal anti-inflammatory drugs (NSAIDs) are the most widely prescribed medication [6-8], but they often cause a dissatisfaction in the treatment of pain [9]. The inability of NSAIDs in overcoming the pain can be caused by the analgesic ceiling effect. In addition, OA is a complex process involving a variety of mechanisms [9]. The combination of analgesics that works by different mechanism may lead to a synergistic effect in the treatment of OA [10, 11]. Non steroidal anti-inflammatory drugs also do not affect the underlying pathogenesis of the disease [12], so they have a minimal role in modifying the course of the disease and improve the quality of life.

A combination drug that can be offered to overcome OA is diacerein and meloxicam. Diacerein is an interleukin 1(IL-1) inhibitor developed for the treatment of OA. Diacerein has efficacy in terms of functional manifestations and structural components of OA [13-15]. It plays an important role in cartilage degradation and stimulation of nociceptive pathways. This mediator shows potent bioactivity in inhibiting synthesis of extracellular matrix (ECM), promoting cartilage damage, and suppressing the expression of an important component of ECM in chondrocytes [16].

Although diacerein can contribute to overcoming the problem of OA, some studies are still debating its benefit. Several randomized controlled trials (RCTs) and meta-analysis studies showed the benefits of diacerein in the treatment of OA and others studies in the Cochrane library declared the absence of significant benefit of diacerein [13, 17-22]. Diacerein was reported having slow-acting properties. The long onset of diacerein cause pain management with diacerein must be combined with other analgesics, such as NSAIDs during the first month of treatment [14]. One of the NSAIDs that can be used is meloxicam that showed benefit in overcoming the pain of OA and rheumatoid disorder [23-26]. Meloxicam has a long half-life (20-24 h) so the using frequency was lower and easier for patients [27]. Based on the above, pain outcomes of OA patients receiving combination therapy of diacerein and meloxicam, and meloxicam alone were compared in this study.

MATERIALS AND METHODS

Study design

This was an open-label, RCT study. The study was conducted during the period January 2016-March 2016 at rumah sakit umum daerah (RSUD) Dr. Mohammad Soewandhie Surabaya. The patient was provided written informed consent. The study was approved by Badan Koordinasi Pendidikan RSUD Dr. Mohammad Soewandhie Surabaya and Badan Kesatuan Bangsa, Politik, dan Perlindungan Masyarakat Kota Surabaya with approval number 070/2554/436.7.8/2016. The consecutive sampling method was used to get participant.

Before intervention was started, screening visit was conducted to determine who will be included in the randomization. At the time of screening, washout was conducted for the analgesic that was used by patients. The washout period was conducted over $5 \times t_{1/2}$ of the drug. If patients experienced pain during the washout period, the patients would be given rescue medication (paracetamol 500 mg, maximum 4 g/d). After a washout period, and the patient experienced pain at least 24 h with scale ≥ 4 , randomization was conducted with blocked randomization method.

Participants in the study were divided into two groups, to receive the combination of diacerein (Artoflam®) 50 mg once daily and

meloxicam 15 mg once daily or to receive meloxicam 15 mg once daily. Drug administration was conducted for 4 w. Follow-up was done every week. Patients were asked to record date and a missed dose, other drugs taken, and changes in the drugs taken. Patients were asked to return the blister of drugs that have been taken and the rest of the drug (both drugs from our study or other drugs consumed by the participant).

Compliance was calculated by comparing the actual amount of drug taken with drugs should be taken during the treatment period. Patients who missed >20% of the drugs were categorized as non-compliant. Patients were discontinued from the study if there were any violation in the criteria of the study, non-compliance with the study protocol, or the incidence of severe side effects.

Patient

The population was outpatients of the orthopedy clinic in RSUD Dr. Mohammad Soewandhie Surabaya. Patients were eligible for the study if they were diagnosed with OA knee by orthopedic specialists, 18-75 y old, had moderate pain when they did not use analgesic (pain score ≥ 4 with 0-10 scale), body mass index (BMI) ≤ 39 kg/m², and agreed to follow the study by signing an informed consent. The definition of knee OA in this study is OA that met clinical criteria and radiological criteria based on Indonesian Rheumatism Association [2].

Exclusion criteria were patient with malignancy; pregnant or using hormonal contraceptive; bleeding disorder or using anticoagulant, or aspirin with daily dose more than 325 mg; uncontrolled hypertension (diastolic >95 or systolic >165), heart failure, or unstable angina; liver and kidney disorder (creatinine clearance ≤ 30 ml/min that was calculated with Cockcroft-Gault formula); psychiatric disorders, using antidepressants, anticonvulsants, antipsychotics, sedatives, or muscle relaxant; drug dependency, drug abuse, or alcohol abuse (≥ 3 glasses/d); history of allergy with drug used in this study; reading, hearing, and speaking inability.

Evaluation of pain outcome

Pain intensity was measured by a combination of Wong Backer Face Rating Scale (WBFPRS) and numeric rating scale (NRS) tools (fig. 1).

Patients were asked to circle one number between 0 and 10 that was the most appropriate to describe the intensity of their pain. Pain intensity was assessed at baseline and every week until the 4th w. The area under the curve (AUC) of pain intensity on each subject was calculated up to 4 w of observation using trapezoidal rule.



Fig. 1: Combination of WBFPRS and NRS tools

Statistical analysis

Data were analyzed with per protocol method. Normality test was analyzed with Shapiro-Wilk test. Data followed a normal curve if $p > 0.05$. Homogeneity test was done by Levene's test. Data were homogeneous if $p > 0.05$. Pain intensity was analyzed using the following method.

1. Paired-sample t-test or Wilcoxon signed rank test was used to compare the efficacy of each group with baseline.
2. Independent-samples t-test or Mann-Whitney U test was used to compare the efficacy between the group receiving combination of diacerein and meloxicam, and meloxicam alone

For all test, data between different groups were significant if $p < 0.05$

RESULTS

A total 68 subject were included in this study. Six subjects were excluded as they used others analgesics, had low compliance, experienced adverse drug reaction (ADR) that could not be tolerated, consumed other OA drug, and experienced getting worse pain. The remaining 62 patients completed the study and included in the analysis (fig. 2.)

Table 1: Demographic and clinical characteristics of participant

No	Patients characteristics	Combination of diacerein dan meloxicam (N=30)	Meloxicam alone (N=32)	p	
1	Gender	Female Σ (%)	24 (80.0%)	25 (78.1%)	1.000
		Male Σ (%)	6 (20.0%)	7 (21.9%)	
2	Age	≥ 60 y	16 (53.3%)	18 (56.3%)	1.000
		<60 y	14 (46.7%)	14 (43.8%)	
		mean \pm SD (y)	61.13 \pm 8.53	60.41 \pm 7.69	
3	BMI	Normal weight Σ (%)	11 (36.7%)	6 (18.8%)	0.136
		Overweight Σ (%)	13 (43.4%)	13 (40.6%)	
		Obese Σ (%)	6 (20.0%)	13 (40.6%)	
4	Pain intensity	mean \pm SD	5.93 \pm 1.51	6.19 \pm 1.42	0.498
5	WOMAC score	Pain (mean \pm SD)	8.07 \pm 3.42	8.81 \pm 3.04	0.660
		Stiffness (mean \pm SD)	3.90 \pm 2.20	4.06 \pm 1.70	0.971
		Physical function (mean \pm SD)	31.70 \pm 11.74	34.34 \pm 10.15	0.346
		Total (mean \pm SD)	43.67 \pm 15.63	47.22 \pm 13.15	0.339
		Menopausal status	Menopause Σ (%)	20 (83.3%)	24 (96.0%)
7	OA grade	Not menopause Σ (%)	4 (16.7%)	1 (4.0%)	0.212
		1 Σ (%)	2 (6.67%)	0 (0.0%)	
		2 Σ (%)	8 (26.7%)	19 (59.4%)	
		3 Σ (%)	16 (53.3%)	8 (25.0%)	
		4 Σ (%)	4 (13.3%)	5 (15.6%)	
8	Duration of OA	≥ 5 y Σ (%)	2 (6.7%)	1 (3.1%)	0.607
		<5 y Σ (%)	28 (93.3%)	31 (96.9%)	
		mean \pm SD (years)	1.13 \pm 1.80	0.75 \pm 1.92	
9.	Involved joints	Unilateral	15 (50.0%)	12 (37.5%)	0.462
		Bilateral	15 (50.0%)	20 (62.5%)	

N: sample size, BMI: body mass index (normal weight ≥ 18 kg/m² and <25 kg/m²; overweight ≥ 25 kg/m² and <30 kg/m²; obese ≥ 30 kg/m²), WOMAC: The Western Ontario and McMaster Universities Arthritis Index




Fig. 2: Study design

The demographic and baseline clinical characteristics of patients were shown in table 1. The two treatment groups were similar with regard to demographic data and baseline clinical characteristic.

Pain outcome evaluation

Pain score decreased significantly in all groups when compared to the baseline values of each group ($p < 0.05$) after 4 w therapies (table 2).

Table 2: Statistical analysis results of pain intensity difference in pre and post treatment

No	Groups	Pain intensity	N	mean±SD	Sig
1	Combination of diacerein and meloxicam	Pre treatment	30	5.93±1.507	0.001*
		Post treatment	30	3.03±1.098	
2	Meloxicam alone	Pre treatment	32	6.19±1.424	0.001*
		Post treatment	32	3.81±1.615	

N: sample size, Sig: significance, SD: Deviation standard, *: $p < 0.05$

Table 3: Statistical analysis results of pain intensity difference between combination of meloxicam and diacerein, and meloxicam alone

No	Time of follow-up	Combination of diacerein dan meloxicam		Meloxicam alone		Sig
		mean±SD	CI 95%	mean±SD	CI 95%	
1.	Week 0	5.93±1.51	5.37-6.50	6.19±1.42	5.67-6.70	0.498
2.	Week 1	4.83±1.60	4.24-5.43	5.34±1.52	4.80-5.89	0.093
3.	Week 2	4.17±1.60	3.57-4.76	4.69±1.66	4.09-5.28	0.101
4.	Week 3	3.37±1.25	2.90-3.83	4.19±1.67	3.58-4.79	0.031*
5.	Week 4	3.03±1.10	2.62-3.44	3.81±1.62	3.23-4.39	0.035*
6.	AUC	16.85±5.22	14.90-18.80	19.22±5.97	17.0-21.37	0.064

SD: Deviation standard, CI 95%: Confident Interval 95%, *: $p < 0.05$

In this study, the combination of meloxicam and diacerein were significantly effective to reduce pain intensity after 4 w. There were no studies that accessed the efficacy of the combination of meloxicam and diacerein. However, there was a similar study conducted by Gupta *et al.* (2012). In that study, 50 mg diacerein and other NSAIDs (diclofenac 75 mg/d), showed significantly different pain scores compared with baseline (after 16 w of therapy) [29]. Randomized controlled trial studies by Shafshak *et al.* (2012) showed administration diacerein (100 mg/d) and diclofenac giving the difference of pain intensity in the pre and post treatment, both at 1 mo ($p = 0.033$) and 2 mo ($p = 0.001$) therapy [30]. A significant reduction effect in pain intensity after 4 w follow-up in this study was supported by the results of the other literature, which said that effects of diacerein appear 2-4 w after therapy, and were significant after 4-8 w [20]. Meloxicam reaches significant effects as an analgesic in 2nd-4th w [27].

Diacerein therapeutic effect on OA based on its ability to inhibit pain and also its affect on the structural components of the joint [15].

In the first week until 2nd w, the difference of pain score between the combination of meloxicam and diacerein, and meloxicam alone could not be seen. Those differences were seen at 3rd weeks ($p < 0.05$). This difference was stable at the end of follow-up (4th w). There was no significant difference in AUC of pain intensity (table 3).

DISCUSSION

This study was designed to assess the efficacy of combination diacerein and meloxicam, and meloxicam alone. In addition, this study was designed to compare the efficacy of combination diacerein and meloxicam, and meloxicam alone after 4 w of therapy.

In this study, meloxicam 15 mg/d has proven effective to give a significant difference in the pain intensity between pre and post treatment after 4 w of therapy. Efficacy of meloxicam in overcoming pain in OA was supported by RCT study by Lund *et al.* (2000). That study showed that meloxicam 15 mg/d was significantly more effective to reduce pain than placebo after 3 w of treatment [24]. Randomized controlled trial study by Yocum *et al.* (2000) also showed the benefits of meloxicam 15 mg/d in patients with hip or knee OA compared to placebo. After 12 w of therapy, there were differences in pain intensity when moved ($p < 0.01$) and pain at rest ($p \leq 0.001$) [23]. The effect of meloxicam in reducing the pain intensity was caused by inhibition the cyclooxygenase (COX) enzyme. The COX-2 enzyme plays a role in the synthesis of prostaglandins, which were the mediators of pain [28].

Diacerein activities were caused by its ability to inhibit IL-1. In the chronic inflammatory process, such as the OA, cells were under pressure and produced cytokines such as IL-1, IL-6, tumor necrosis factor- α (TNF- α) which can cause damage to cells and phospholipids membrane release [14]. In structural components, IL-1 plays an important role in cartilage degradation [16].

When it is linked to the response to pain, mechanism of action of IL-1 β able can up-regulate of pro-nociceptive mediators, such as nerve growth factor (NGF), which was known as a neurotrophic factor that played an important role in the process of pain. Interleukin 1 β can signal through a signal cascade that leads to the release and/or activation of nociceptive molecules such as prostaglandins, IL-6, substance P, and matrix metalloproteinase 9 (MMP 9). The action of IL-1 β may also occur directly on nociceptors. The receptor for IL-1 is expressed in sensory neurons. Interleukin-1 β can modulate neuronal accessibility to affect neuronal receptors such as sodium channels, gamma-aminobutyric acid (GABA), and n-methyl-d-aspartate (NMDA) receptors [31]. With a complex mechanism,

diacerein can reduce the intensity of pain and prevents further cartilage damage.

When it was compared with meloxicam alone, the combination of meloxicam and diacerein showed no significant difference in pain intensity at 1st and 2nd w. It could be caused by the onset of diacerein which was achieved at 2nd to 4th w after administration. The difference in pain intensity on both of groups can be observed at the 3rd week 4th weeks. Meloxicam alone group had greater pain intensity than its combination with diacerein.

When they were compared using AUC parameters, the combination of meloxicam and diacerein and meloxicam alone did not show a significant difference. Area under the curve data is the result of merging the intensity of pain from time to time. Pain intensity data can be transformed to the AUC to access the benefits of analgesic [32]. Compared with measurements at the end of study (EOS), the results of trials using the AUC provide smaller effect estimation but better precision. Area under the curve values gives the possibility to maintain the distinction treatment group by calculating the exact onset and offset of action of the drug. Trial with the rapid acting drug showed that AUC was more sensitive than EOS to detect treatment differences [33]. Analysis of the AUC was more stable and sensitive to see the interpatient difference than other measurements. Area under the curve described the cumulative response of an intervention, but did not provide information about the onset of analgesic effect [34].

Despite they have the different working mechanism and can support each other, the addition of diacerein to meloxicam therapy provided no significant difference in AUC of pain intensity. Several other studies supported the insignificant outcomes of pain intensity between the combination of diacerein and meloxicam with meloxicam alone. The results of this research were supported by a similar study conducted by Gupta *et al.* (2012). In that study, diacerein 50 mg in combination with other NSAIDs (diclofenac 75 mg) per day has shown significant differences in pain scores after 16 w of therapy compared with NSAIDs alone. That study did not explain the differences in pain scores over time between the combination group and single group. So, it was not known when these differences began to appear [29]. If it was assumed differences emerged at week 16th, the longer observation was needed in order to see the effect of the combination of meloxicam and diacerein.

Randomized controlled trial study by Shafshak *et al.* (2012), in patients receiving diacerein 100 mg/d for 2 mo vs diclofenac vs diacerein, found that in all three groups, there were no significant difference in pain intensity, both at 1 mo ($p = 0.493$) and 2 mo ($p = 0.325$) therapy [30]. Another study by Singh *et al.* (2012) also showed the comparison of addition NSAID (diclofenac) in patients with knee OA who consumed diacerein. The study was conducted for 3 mo. The combination group used diacerein 50 mg/d in the first month, 2 × 50 mg/d in 2nd and 3rd and sustained release diclofenac 75 mg/d from 1st to 3rd mo. Comparison group only used sustained release diclofenac 75 mg/d. After 3 mo, administration of diacerein and diclofenac showed a significant difference in pain intensity compared to diclofenac alone [35]. The difference above was appeared in a longer time (3 mo) compared to our study. That study did not explain about differences in pain scores over time, between the combination group and single group, so it was unknown when these differences were begun. If it was assumed in Singh *et al.* study that differences were shown at the 3rd mo (week 12), we needed longer observation in order to see the different between the combination of diacerein and meloxicam, and meloxicam alone. In addition, that study used different dose every month (50 mg/d of diacerein in the first month, followed by 100 mg/d in the next 2 mo). This dose differences could affect the outcome differences.

The difference of efficacy that was shown at 3rd and 4th w indicated that combination of meloxicam and diacerein had the potential benefits in the treatment of OA. Effect of diacerein was begun at 2nd to 4th w and significant at 4th-8th w [14]. Thus, we need longer observation up to 8 w in order to see the differences in the AUC of pain intensity. The differences in pain intensity between 2 groups become insignificant can be caused by small sample size, so we required the addition of large samples. In addition, different baseline

characteristics among study could influence the results, such as gender, BMI, and duration of suffering from OA.

There were differences in the proportion of men and women in the study conducted by Gupta *et al.* (2012) with our study. Our study was dominated by women (78.1%-80.00%), whereas in the study of Gupta *et al.*, the proportion between male and female was comparable (male: female = 2: 3). Gender was known affecting response to pain experienced. The study that was conducted by Tonelli *et al.* (2011) showed that women had a greater pain intensity than men in patients with osteoarthritis ($p = 0.04$) [36]. Differences in BMI also can contribute to pain intensity difference in OA patients. A study by Oyeyemi *et al.* (2013) showed that BMI influenced the effectiveness of knee OA treatment [37]. The significant differences in pain intensity between the normal weight and overweight ($p = 0.016$) patient and between normal weight and obese patient ($p = 0.005$) was found.

CONCLUSION

Combination therapy of diacerein and meloxicam was more effective than meloxicam alone. A significant effect of a combination therapy of diacerein and meloxicam occurred at 3rd w. The prolong study in order to get the differences in AUC pain score are needed. In addition, the cost-effectiveness analysis was needed to see the benefit of that combination compared with the single therapy.

ACKNOWLEDGEMENT

The authors thank all of the subjects for participating in this study. We also acknowledge to orthopedic specialists in orthopedic departement of RSUD Dr. Mohammad Soewandhie Surabaya (dr. Bimo Sasono, dr. Carlos Supriyantono Binti, Sp. OT and dr. Gede Chandra Purnama Yudha, Sp. OT.) that helped the author during data collecting.

AUTHOR CONTRIBUTION

Author, Ni Made Oka Dwicandra, made substantial contributions to conception and design, acquisition of data, and analysis and interpretation of data. Co author, Antonious Adji Prayitno Setiadi, participated in drafting the article and revising it critically for important intellectual content.

AFFILIATION

Ni Made Oka Dwicandra

Pharmacy Department, Institute of Health Sciences Medika Persada Bali, Denpasar, Bali, Indonesia

Antonious Adji Prayitno Setiadi

Departement of Clinical Pharmacy, Pharmacy Faculty, University of Surabaya, Surabaya, Jawa Timur, Indonesia

LIST OF ABBREVIATION

AUC: area under the curve, BMI: body mass index, ECM: extracellular matrix, EOS: end of study, GABA: gamma-aminobutyric acid, IL: interleukin, MMP: matrix metalloproteinase, NGF: nerve growth factor, NMDA: n-methyl-d-aspartate, NRS: numeric rating scale, NSAID: non steroidal anti-inflammatory drugs, OA: osteoarthritis, RCT: randomized controlled trial, RSUD: rumah sakit umum daerah, TNF: tumor necrosis factor, WBFRRS: wong backer faces rating scale, WHO: world health organization

FUNDING

No specific funding was received for this study

CONFLICTS OF INTERESTS

All authors have none to declare

REFERENCES

1. Alldredge BK, Affairs A, Francisco S, Corelli RL, Ernst ME, City I, *et al.* Koda-Kimble and Young's Applied Therapeutic: The Clinical Use of Drug. 10th ed. Philadelphia: Lippincot Williams and Wilkins; 2013.

2. The Indonesian Rheumatism Association. Diagnosis dan Penatalaksanaan Osteoarthritis. Jakarta: The Indonesian Rheumatism Association; 2014.
3. Jena M, Mishra S, Pradhan S, Jena S, Mishra SS. Chronic pain, its management and psychological issues: a review. *Asian J Pharm Clin Res* 2015;8:42-7.
4. Łastowiecka E, Bugajska J, Najmiec A, Rell-Bakalarska M, Bownik I, Jedryka-Góral A. Occupational work and quality of life in osteoarthritis patients. *Rheumatol Int* 2006;27:131-9.
5. Tak S, Laffrey S. Life satisfaction and its correlates in older women with osteoarthritis. *Orthopaedic Nursing* 2003;22:182-9.
6. Conaghan P, Rannou F, Arden N, Everett SV, Balshaw R, Peloso PM, *et al.* Inadequate pain relief (IPR) in knee osteoarthritis: what does it look like? a European survey of osteoarthritis real world therapies (SORT). *Osteoarthritis and Cartilage J* 2012;20:S178.
7. Jameson K, Balshaw R, Phillips C, Martin GR, Everett SV, Watson DJ, *et al.* PMS59 inadequate pain relief in knee osteoarthritis and patient reported outcomes: a survey of osteoarthritis real world therapies (SORT) in the United Kingdom. *Value Health* 2011;14:A313.
8. Conaghan PG, Peloso PM, Everett SV, Rajagopalan S, Black CM, Mavros P, *et al.* Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies. *Rheumatology (Oxford)* 2015;54:270-7.
9. Mercadante S, Casuccio A, Agnello A, Pumo S, Kargar J, Garofalo S. Analgesic effects of nonsteroidal anti-inflammatory drugs in cancer pain due to somatic or visceral mechanisms. *J Pain Symptom Manage* 1999;17:351-6.
10. Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. *Curr Med Res Opin* 2011;27:2361-72.
11. Ohtori S, Inoue G, Orita S, Takaso M, Eguchi Y, Ochiai N. Efficacy of combination of meloxicam and pregabalin for pain in knee osteoarthritis. *Yonsei Med J* 2013;54:1253-8.
12. Colville-Nash P, Willoughby D. COX-1, COX-2 and articular joint disease: a role for chondroprotective agents. *Biorheology* 2002;39:171-9.
13. Fidelix T, Macedo C, Maxwell L, Fernandes Moça Trevisani V. Diacerein for osteoarthritis. *Cochrane Database of Systematic Reviews*; 2014.
14. Medhi B. Diacerein: a new disease modulating agent in osteoarthritis. *Indian J Physical Med Rehabilitation* 2007;18:48-52.
15. Mahajan A, Singh K, Tandon VR, Kumar S, Kumar H. Diacerein: a new symptomatic slow acting drug for Osteoarthritis. *JK Sci* 2006;8:173-5.
16. Lee AS, Ellman MB, Yan D, Kroin JS, Cole BJ, van Wijnen AJ, *et al.* A current review of molecular mechanisms regarding osteoarthritis and pain. *Gene* 2013;527:440-7.
17. Kongtharvonskul J, Anothaisintawee T, McEvoy M, Attia J, Woratanarat P, Thakkinian A. Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: a systematic review and network meta-analysis. *Eur J Med Res* 2015;20:1-11.
18. Rintelen B, Neumann K, Leeb B. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. *Arch Intern Med* 2006;166:1889-906.
19. Bartels EM, Bliddal H, Schøndorff PK, Altman RD, Zhang W, Christensen R. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. *Osteoarthritis Cartilage* 2010;18:289-96.
20. Pelletier J, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, *et al.* Efficacy and safety of diacerein in osteoarthritis of the knee. *Arthritis Rheum* 2000;43:2339-48.
21. Pavelka K, Trc T, Karpas K, Vítek P, Sedláčková M, Vlasáková V, *et al.* The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period. *Arthritis Rheum* 2007;56:4055-64.
22. Mirunalini R, Chandrasekaran M, Manimekalai K. Efficacy of chondroitin sulfate with glucosamine versus diacerein in grade ii and iii osteoarthritis knee: a randomized comparative study. *Asian J Pharm Clin Res* 2015;8:42-4.
23. Yocum D, Fleischmann R, Dalgin P, Caldwell J, Hall D, Roszko P. Safety and efficacy of meloxicam in the treatment of osteoarthritis a 12-week, double-blind, multiple-dose, placebo-controlled trial. *Arch Intern Med* 2000;160:2947-54.
24. Lund B, Distel M, Bluhmki E. A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. *Scand J Rheumatol* 1998;27:32-7.
25. Goei HS, Lund B, Distel M, Bluhmki E. A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. *Osteoarthritis Cartilage* 1997;5:283-8.
26. Zeidler H, Kaltwasser J, Leonard J, Kohlmann T, Sigmund R, Degner F, *et al.* Prescription and tolerability of meloxicam in day-to-day practice: postmarketing observational cohort study of 13,307 patients in Germany. *J Clin Rheumatol* 2002;8:305-15.
27. Tacca M Del, Colucci R, Fornai M, Blandizzi C. Efficacy and tolerability of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug. *Clin Drug Inves* 2002;11:1-22.
28. Dipiro J, Talbert R, Yee G, Matzke G, Wells B, Posey L. *Pharmacotherapy: pathophysiologic approach*. 7th ed. USA: The McGraw-Hill Companies, Inc; 2008.
29. Gupta N, Datta S. Efficacy and safety of diacerein and diclofenac in knee osteoarthritis in Indian patients-a prospective randomized open label study. *J Biomed Sci* 2012;1:1-14.
30. Shafshak TS, Shaheen EM, Hussein N, Hafez AA. The efficacy of diacerein with and without diclofenac sodium on knee pain severity and walking time in patients with knee osteoarthritis. *Indian J Sci Res* 2014;3:2012-5.
31. Rena K, Torres R. Role of interleukin-1 β during pain and inflammation. *Brain Res Rev* 2011;60:57-64.
32. Lee CJ, Lee LH, Wu CL, Lee BR, Chen ML. *Clinical trials of drug and biopharmaceuticals*. USA: Taylor and Francis Group; 2006.
33. Pham B, Cranney A, Boers M, Verhoeven A, Wells G, Tugwell P. Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials. *J Rheumatol* 1999;26:712-6.
34. Schiff M. A rationale for the use of summary measurements for the assessment of the effects of rheumatoid arthritis therapies. *Clin Ther* 2003;25:993-1001.
35. Singh K, Sharma R, Rai J. Diacerein as adjuvant to diclofenac sodium in osteoarthritis knee. *Int J Rheum Dis* 2012;15:69-77.
36. Tonelli SM, Rakel BA, Cooper NA, Angstrom WL, Sluka KA. Women with knee osteoarthritis have more pain and poorer function than men, but similar physical activity prior to total knee replacement. *Biol Sex Differ* 2011;2:1-12.
37. Oyeyemi AL. Body mass index, pain and function in individuals with knee osteoarthritis. *Nigerian Med J* 2013;54:230-5.

How to cite this article

- Ni Made Oka Dwicandra, Antonious Adji Prayitno Setiadi. Comparison of pain score in osteoarthritis patients treated with a combination of diacerein and meloxicam and meloxicam alone. *Int J Pharm Pharm Sci* 2017;9(6):69-73.

INTERNATIONAL JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

ISSN 0975-1491

Home | About | Login | Register | Search | Current | Archives | Editorial Board |
Submission | Instructions to Authors | Contact Us |

USER

Search Articles

All

Search

Username

Password

 Remember me

Login



ICV (2016): 102.3
Impact (Cites per doc)- 0.75
(SCImago, SJR 2017)



International Journal of
Pharmacy and...



BECOME REVIEWER

JOURNAL METRICS

Source Normalized
Impact per Paper
(SNIP): 0.803

International Journal of Pharmacy and Pharmaceutical Sciences

Welcome to IJPPS ISSN- 0975 – 1491

International Journal of Pharmacy and Pharmaceutical Sciences (Int J Pharm Pharm Sci) is peer-reviewed, monthly (Onward April 2014) open access Journal. IJPPS publishes original research work that contributes significantly to advance the scientific knowledge in pharmacy and pharmaceutical sciences including

- Pharmaceutical Technology, Pharmaceutics, Novel Drug Delivery, Biopharmaceutics, Pharmacokinetics
- Pharmacognosy and Natural Product Research
- Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmaceutical Analysis
- Pharmacology, Pharmacy Practice, Clinical and Hospital Pharmacy
- Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics, Pharmacoeconomics
- Research outcomes from medical sciences/case study and biotechnology of pharmaceutical interest are also considered.

IJPPS publishes original research work either as an Original Article or as a Short Communication. Review articles on the current topic under mentioned scopes are also considered for publication. In addition, a hypothesis is also invited now for the publication onwards March 2016.


Journals of Innovare Academic Sciences have made their presence in short span of time amongst International community with great impact.

Before submission of the manuscript, please see "**Minimum standards for manuscripts**" for consideration of Publication in IJPPS ([Click Here](#))

Abstracting and Indexing

Google Scholar, Elsevier products (EBSCO and EMBASE), SCI mago (SJR, upto 2016), CNKI (China Knowledge Resource Integrated Database), CAS, CASSI (American Chemical Society), Index Copernicus, ICAAP, PSOAR, Open-J-Gate, Indian Citation Index (ICI), Index Medicus for WHO South-East Asia (IMSEAR), OAI, LOCKKS, OCLC (World Digital Collection Gateway), UIUC.

Impact per
Publication (IPP):
0.512



SCImago Journal
Rank (SJR): 0.22


ISSN: 0975-1491


3rd International Conference
ON
**Academic and Industrial Innovations: Transitions in Pharmaceutical,
Medical and Biosciences**
(22-23 Oct 2018)
Kala Academy, Goa, India


Is your Academic organization
is ready for getting excellence?

Here is the **Solution!**

 **Knowledge product**
e-journals & Print journals
in different discipline
10+ Journals
10,000+ Published article

 **IP service**
Assisting you in carrying out
the patent searches,
preparing, drafting, filing and
prosecuting the patent
applications

Our Journals || Open Access Policy || Publication Ethics

The publication is licensed under a Creative Commons License (CC BY) . View Legal Code

Copyright © 2017 All Rights Reserved: **Innovare Academic Sciences** || Powered By **CyberDairy**

INTERNATIONAL JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

ISSN 0975-1491

[Home](#)[About](#)[Login](#)[Register](#)[Search](#)[Current](#)[Archives](#)[Editorial Board](#)[Submission](#)[Instructions to Authors](#)[Contact Us](#)

All

Search

USER

Username

Password

 Remember me

Login



ICV (2016): 102.3

Impact (Cites per doc)- 0.75

(SCImago, SJR 2017)



ELSEVIER

International Journal of
Pharmacy and...

Q3

Pharmaceutical
Science

best quartile

SJR 2017

0.22

powered by scimagojr.com

BECOME REVIEWER

JOURNAL METRICS

Source Normalized
Impact per Paper
(SNIP): 0.803

Editorial Board

Editor-in-Chief

Prof. M. S. Bhatia, India
(Bharati Vidyapeeth College of Pharmacy, Kolhapur, India)
Email: manish.bhatia@bharativedyapeeth.edu
Email: editor@ijppsjournal.com

Associate Editors

Dr. Avijeet Jain, India
(Shri Sathya Sai Institute of Pharmaceutical Sciences, Bhopal, India)
Email: avijeet_9826275340@rediffmail.com

Diah Ayu Maharani
Department of Preventive and Public Health, Dentistry Faculty of Dentistry, University of Indonesia
Email: raniabdillah@gmail.com

Dr. Subhash C Mandal, India
(Department of Pharmaceutical Technology, Jadavpur University, Kolkata, India)
Email: subhashmandal@yahoo.com

Dr. Lokesh Deb, India
(Medicinal Plants and Horticultural Resources Division, Institute of Bioresources and Sustainable Development (IBSD), Department of Biotechnology, Government of India, Takyelpat Institutional Area, Imphal, Manipur, India)
Email: lokesh_deb@rediffmail.com

Dr. Wong Tin Wui, Malaysia
(Non-Destructive Biomedical and Pharmaceutical Research Center, University of Technology MARA, Malasiya)
Email: wongtinwui@yahoo.com

Assistant Editor

Dr. Idress Hamad Attittala, Libya
(Omar El-Mukhtar University, Faculty of Science, Botany Department, El-Beida, Libya)
Email: idressattittalla2004@yahoo.com

Dr. Alok Nahata, Malaysia
(Alor Star, Malaysia)
Email: aloknahata@gmail.com

Executive Editor

Mr. Niranjana Pathak, India
(Dept. of Pharmaceutical Sciences, Dr H S Gour Central University, Saugor, India)
Email: niranjanaathaklib@gmail.com

Editorial Board Members

Impact per
Publication (IPP):
0.512

SCImago Journal
Rank (SJR): 0.22

ISSN: 0975-1491

Dr. Furhan Iqbal Bahauddin Zakariya University Multan, Pakistan	Dr. Javed Intekhab G. F. College (Rohilkhand University), Shahjahanpur, U.P., India
Dr. Ebtessam Ahmed Mohammed Essa Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, Egypt	Dr. Manish P. Patel Dept. of Pharmaceutics and Pharmaceutical Technology, Nootan Pharmacy College, Visnagar, Gujarat, India
Dr. Syed Muhammad Farid Hasan Faculty of Pharmacy, University of Karachi, Karachi, Pakistan	Dr. Narendra Babu Shivanagere Nagojappa J.N. Medical College, KLE University, Belgaum, Karnataka, India
Dr. Abdel Raheim Mohammed Ahmed Donia College of Pharmacy – Salman Bin Abdul Aziz University, Egypt	Dr. C. Chellaram Vel Tech Multi Tech Engg. College, Chennai, India
Dr. Pranay Jain Institute of Engineering & Technology, Kurukshetra University, Kurukshetra, Haryana, India	Dr. Mehdi Shafiee Ardestani Department of Medicinal Chemistry and Radiopharmacy, Tehran University of Medical Sciences, Tehran, Iran
Dr. Dr. Niaz Ali Institute of Basic Medical Sciences, Khyber Medical University, Peshawar, Pakistan	Dr. Amal Amin Mohamed Plant Biochemistry Department; Agriculture Division -National Research Center, Dokki, Cairo, Egypt
Dr. M. Saeed Arayne Chairman, Department of Chemistry, University of Karachi, Pakistan	Dr. Rabab Kamel Mahmoud National Research Center, Cairo, Egypt
Dr. Wanzala Wycliffe School of Pure and Applied Sciences, South Eastern Kenya University, Kenya	Dr. Syed Adnan Ali Shah Universiti Teknologi MARA (UiTM), Puncak Alam Campus, Bandar Puncak Alam, Selangor D. E., Malaysia
Dr. Mayuree Tangkiatcumjai Faculty of Pharmacy, Srinakharinwirot University, Ongkharak, Nakhonnayok, Thailand	Dr. Sat Pal Singh Bisht Roland Institute of Pharmaceutical Sciences Berhampur, Orissa, India.
Dr. Anup Naha Dept. of Pharmaceutic, MCOPS, Manipal, Karnataka, India	Dr. Shahu Ingole Smt. Kashibai Navale Medical College & Hospital, Pune India
Dr. Jagdish Labhubhai Kakadiya Indubhai Patel College of Pharmacy and Research Centre, Petlad-Khambhat Road, Dharmaj, Anand, Gujarat, India	Dr. Gina Samy El-Feky Pharmaceutics Department, Faculty of Pharmacy, Modern Science and Arts University, Egypt
Dr. Maha Ali Eissa Ahmed Department of Pharmacology, Faculty of Pharmacy, MISR University for Science and Technology (MUST), Giza Governorate, Egypt.	Dr. Abdalla Ahmed Elbashir Ahmed Khartoum University, Sudan
Dr. Rajesh Mukthavaram Health Science Drive, University of California, San Diego, Lajolla, CA, California, USA	Dr. Yesudass Dominic Ravichandran School of Advanced Sciences, VIT University, Vellore, Tamil Nadu, India
Dr. Saifullah Khan International Islamic University, Malaysia	Dr. Seema Akbar Research Institute of Unani Medicine, The University of Kashmir Campus, Srinagar, J. & K., India
Norhaniza Aminudin Institute of Biological Sciences, Faculty of	Dr. P. Thillai Arasu Department of Chemistry, Wollega University, Nekemta, Ethiopia

- Science, University of Malaya, Kuala Lumpur, Malaysia.
- Dr. Shazia Jamshed
Kulliyah of Pharmacy, International Islamic University Malaysia (IIUM), Kuantan, Pahang, Malaysia
- Dr. Mayuree Tangkiatkumjai
Department of Clinical Pharmacy and Social Pharmacy Faculty of Pharmacy, Srinakharinwirot University, Nakhonnayok, Thailand
- Dr. İsmail Murat Palabiyik
Faculty of Pharmacy, University of Ankara, Tandoğan, Ankara, Turkey
- Nadeem A. Kizilbash
Faculty of Medicine, Northern Border University Arar, Saudi Arabia
- Dr. Debajit Kalita
Department of Botany, Morigaon College, Assam, India
- Dr. Seyed Mohammad
Department of Biology, Faculty of Basic Sciences, University of Mazandaran, Babolsar, Iran
- Dr. Shalini Sivadasan
Faculty of pharmacy, AIMST University, Semeling, Kedah, Malaysia
- Dr. Sujimon Tanvichien
Srinakharinwirot University Nakornayok Rd. A. Ongkarak T.Ongkarak, Nakornayok, Thailand
- Prof. Dr.-Ing. habil. Dr. h. c. Lothar Mörl
Institute für Apparate- und Umwelttechnik Otto-von-Guericke-Universität Magdeburg, Germany
- Dr. V. Ravichandran
Faculty of Pharmacy, AIMST University, Semeling, Kedah, Malaysia
- Dr. Zahid Hussain
Department of Pharmaceutics, Faculty of Pharmacy, Universiti Teknologi MARA, Puncak Alam Campus, Malaysia
- Dr. Ajay Kumar Meena
Department of AYUSH, Ministry of Health & Family Welfare, Government of India, India
- Dr. Ashish C. Suthar
Herbal R & D, Piramal Life Sciences Ltd., Mumbai, India
- Dr. Manish A. Rachchh
Pharmacological Research and IPR University road, Rajkot, Gujarat, India
- Dr. Sooraj S. Nath
Safi Institute of Advanced Study, Kozhikode, India
- Dr. Erum Shireen
Dept. of Biochemistry, University of Karachi, Pakistan
- Dr. M. M. Gupta
School of Pharmacy, Faculty of Medical Sciences, The University of The West India, India
- Dr. Najma Sultana
United Biotechnologies, Karachi, Pakistan
- Dr. Sivakumar P
Department of Petroleum Engineering, JCT College of Engineering and Technology, Pichanur, Tamil Nadu, India
- Dr. Evren Algin Yapar
Department in Ministry of Health, Turkish Medicines and Medical Devices Agency, Ankara, Turkey
- Dr. Vishal Vijay Pandey
Jayawantrao Sawant College of Pharmacy & Research, Hadapsar, Pune, India
- Dr. Shamkuwar Prashant Babarao
Government College of Pharmacy, Thiba Palace, Ratnagiri, India
- Dr. S. K. Starling
Department of Chemistry, Mewar University Chittorgarh, Rajasthan, India
- Dr. Syed Sajjad Hussien
Manipal College of Pharmaceutical Sciences, Manipal University, India
- Dr. Ahmed Osman
Department of Psychology, Faculty of Education, Assiut University, Malaysia
- Dr. Abdel-Tawab Halim Mossa Abd El-Aziz
Department of Pesticide Chemistry, National Research Centre (NRC) Dokki, Cairo, Egypt
- Dr. V. Vinod Prabhu
Department of Biochemistry, University of Madras, Guindy campus, Tamil Nadu, India
- Dr. Ching Siew Mooi
University Putra, Malaysia
- Dr. Asif Husain
Jamia Hamdard University, New Delhi, India
- Dr. Muhammad Shahzad Aslam
School of Bioprocess Engineering, Universiti Malaysia Perlis, Kompleks Pusat Pengajian Jejawi, Arau, Perlis

Kiran Kumar Chereddy
Manager at Novartis Pharma AG
Postfach 4002, Basel
Switzerland

Dr. Fahd M. Abd Al Galil
Department of Zoology, Faculty of Applied
Science, Thamar University, Yemen

Dr. Priyanka Bhatt
Department of Pharmaceutical Sciences,
College of Pharmacy, University of South
Florida, USA


Dr. Beril Anilanmert
Istanbul University-Cerrahpasa Institute of
Forensic Sciences, Cerrahpasa/Istanbul

Dr. Gláucio Diré Feliciano
State University Center Foundation of the
West Zone / Rio de Janeiro, Brazil

Dr Dilipkumar Pal
Department of Pharmaceutical Sciences,
Guru Ghasidash Vishwavidyalaya, Bilaspur,
C.G., 495 009, India

Ali Abdullah Ali Al-yahawi
Assistant Professor of Clinical Pharmacy
& Therapeutics, Yemen

Our Journals || Open Access Policy || Publication Ethics

The publication is licensed under a Creative Commons License (CC BY) . View Legal Code

Copyright © 2017 All Rights Reserved: **Innovare Academic Sciences** || Powered By **CyberDairy**

Home | About | Login | Register | Search | Current | Archives | Editorial Board |
Submission | Instructions to Authors | Contact Us

USERUsername Password Remember me

ICV (2016): 102.3
Impact (Cites per doc)- 0.75
(SCImago, SJR 2017)

International Journal of
Pharmacy and...

Q3 Pharmaceutical
Science
best quartile

SJR 2017
0.22
powered by scimagojr.com

**JOURNAL
METRICS**

Source Normalized
Impact per Paper
(SNIP): 0.803

Search Articles

All

Search

Vol 9, Issue 6, 2017**Table of Contents****Letter to Editor****COMPARISON BETWEEN GENERIC DRUGS AND BRAND NAME DRUGS FROM BIOEQUIVALENCE AND THERMOEQUIVALENCE PROSPECTIVE**

Mosab Arafat, Zahaa Ahmed, Osama Arafat

Abstract || View PDF || View HTML || Download PDF || DOI: 10.22159/ijpps.2017v9i6.18735

Pages: 1-4 | Share

Original Article(s)**STUDIES ON SIDA ACUTA HYDROGEL I: PROCESSING AND PHYSICOCHEMICAL PROPERTIES OF THE DERIVED HYDROGEL OBTAINED FROM SOUTH EAST NIGERIA**

Okafo Sinodukoo Eziuzo, Chukwu Amarauche

Abstract || View PDF || View HTML || Download PDF || DOI: 10.22159/ijpps.2017v9i6.10097

Pages: 5-11 | Share

FORMULATION OF SOLID DOSAGE FORM CONTAINING CLOPIDOGREL AND CILOSTAZOL AND ITS HPLC ANALYSIS

Asha Thomas, Suraj Bhosale, Rabindra Nanda

Abstract || View PDF || View HTML || Download PDF || DOI: 10.22159/ijpps.2017v9i6.13987

Pages: 12-18 | Share

SELF MEDICATION PRACTICE AMONG URBAN SLUM DWELLERS IN UDUPI TALUK, KARNATAKA, INDIA

Pranav V, Prakash Narayanan, Vasudeva Guddattu

Abstract || View PDF || View HTML || Download PDF || DOI: 10.22159/ijpps.2017v9i6.15950

Pages: 19-23 | Share

PHYTOCHEMICAL ANALYSIS AND IMMUNO-MODULATORY EFFECT OF MORINGA OLEIFERA FLOWERS

Venkatasthya Sai Appala Raju Velaga, Nagaraja Suryadevara, Lim Li Chee, Nahlah Elkudssiah Ismail

Abstract || View PDF || View HTML || Download PDF || DOI: 10.22159/ijpps.2017v9i6.16285

Pages: 24-28 | Share

PHYTOCHEMICAL INVESTIGATION, GC-MS PROFILE AND ANTIMICROBIAL ACTIVITY OF A

Impact per

Publication (IPP):
0.512SCImago Journal
Rank (SJR): 0.22

ISSN: 0975-1491

MEDICINAL PLANT RUTA GRAVEOLENS L. FROM ETHIOPIA

Henok Gulilat Azalework, Sahabjada ., Asif Jafri, Md Arshad, Tabarak Malik

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.16812Pages: 29-34 | [Share](#)**ANTIBACTERIAL ACTIVITY OF MENTHA PULEGIUM ESSENTIAL OIL AGAINST AVIAN ISOLATED ESBL PRODUCING BACTERIA AND ITS SYNERGISTIC POTENTIAL WITH ANTIBIOTICS**

Fatima Yahiaoui, Qada Benameur, Meriem Hind Ben-Mahdi

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.17092Pages: 35-41 | [Share](#)**CAFFEINEAS A PROMISING ANTIFIBROTIC AGENT AGAINST CCL4-INDUCED LIVER FIBROSIS**

Mostafa Kamal Mohamed, Marwa Mahmoud Khalaf, Amira Morad Abo-Youssef, Ali Ahmed Abo-Saif

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.17143Pages: 42-47 | [Share](#)**IN VIVO ANTI-DIABETIC ACTIVITY EVALUATION OF THE BARK OF CASCABELA THEVETIA L. IN STREPTOZOTOCIN INDUCED DIABETIC RATS**

Neelutpal Gogoi, Biman Bhuyan

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.17200Pages: 48-53 | [Share](#)**EFFECT OF EXTRACTS AQUEOUS OF PHRAGMITES AUSTRALIS ON CARBOHYDRATE METABOLISM, SOME ENZYME ACTIVITIES AND PANCREATIC ISLET TISSUE IN ALLOXAN-INDUCED DIABETIC RATS**

Samir Derouiche, Manel Azzi, Abir Hamida

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.17321Pages: 54-58 | [Share](#)**SERUM NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL) AS A PREDICTIVE BIOMARKER OF KIDNEY INJURY IN RENAL TRANSPLANTED PATIENTS AND CHRONIC KIDNEY DISEASE**

Zainab A.A. Al-Shamma, Nahla Ghanim Alklyali, Intesar Yousif Alani

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.17510Pages: 59-63 | [Share](#)**ALPHA AMYLASE AND ALPHA GLUCOSIDASE INHIBITION ACTIVITY OF SELECTED EDIBLE SEAWEEDS FROM SOUTH COAST AREA OF INDIA**

P. Reka, Thahira Banu A., M. Seethalakshmi

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.17684Pages: 64-68 | [Share](#)**COMPARISON OF PAIN SCORE IN OSTEOARTHRITIS PATIENTS TREATED WITH A COMBINATION OF DIACEREIN AND MELOXICAM AND MELOXICAM ALONE**

Ni Made Oka Dwicandra, Antonious Adji Prayitno Setiadi

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.17671Pages: 69-73 | [Share](#)**DNA-BASED HYBRID LIQUID CRYSTALLINE NANO ORGANOMETALLIC COMPOSITES FOR TARGETED DRUG DELIVERY IN NEUTRON CAPTURE THERAPY**

Slivkina I, Kondrashina O. V., Halahakoon M. A. J, Belenova Alena Sergeevna

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.17991Pages: 74-79 | [Share](#)**SAFETY SIGNAL DETECTION OF CARDIAC DISORDERS ADVERSE DRUG EVENTS FOR AZITHROMYCIN IN PEDIATRIC POPULATION USING HEALTH CANADA ADVERSE EVENT REPORTING SYSTEM DATABASE**

Gaurav Kumar Shah, Mukesh Kumar Patel, Dr. Bhanwarlal Jat

[Abstract](#) || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.18020

Pages: 80-84 | [Share](#)

A STUDY ON THE EFFECT OF LOW MOLECULAR WEIGHT ON POTASSIUM HOMEOSTASIS IN PATIENTS ADMINISTERED HEPARIN FOR THROMBOPROPHYLAXIS IN A TERTIARY CARE HOSPITAL

S. Shanmugapriya, K. Bhuvaneshwari, K. Rashmi

[Abstract](#) || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.18191

Pages: 85-89 | [Share](#)

ARTEMETHER LOADED ETHYLCELLULOSE NANOSUSPENSIONS: EFFECTS OF FORMULATION VARIABLES, PHYSICAL STABILITY AND DRUG RELEASE PROFILE

Nasrin E. Khalifa, Abubakr O. Nur, Zuheir A. Osman

[Abstract](#) || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.18321

Pages: 90-96 | [Share](#)

CHEMICAL CHARACTERIZATION AND ANTIMICROBIAL ACTIVITY OF JORDANIAN PROPOLIS AND NIGELLA SATIVA SEED OIL AGAINST CLINICALLY ISOLATED MICROORGANISMS

Sabah E Al-Muhtaseb, Najah I Al-Muhtaseb, Mahmoud Al-Masri, Elham N Al-Kaissi, Ibrahim S Al-Adham, Amjad Abu Sirhan

[Abstract](#) || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.18335

Pages: 97-102 | [Share](#)

PROTECTIVE ROLE OF DAIDZEIN AGAINST CYCLOPHOSPHAMIDE INDUCED NEPHROTOXICITY IN EXPERIMENTAL RATS

Sanjiv Karale, Jagadish V Kamath

[Abstract](#) || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.18516

Pages: 103-107 | [Share](#)

HYPERHOMOCYSTEINEMIA LEAD TO TRANSMURAL INFLAMMATION OF COLON AND INCREASE SEVERITY OF DISEASE IN ACETIC ACID-INDUCED COLITIS IN RAT

Lamda Souad, Naimi Dalila, Aggoun Cherifa

[Abstract](#) || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.16036

Pages: 108-116 | [Share](#)

DEVELOPMENT AND VALIDATION OF UV SPECTROSCOPIC METHODS FOR SIMULTANEOUS ESTIMATION OF SALBUTAMOL SULPHATE AND DOXOPHYLLINE IN COMBINED SOLID DOSAGE FORM

Anjoo Kamboj, Pawan Sidana, Upendra K. Jain

[Abstract](#) || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.14938

Pages: 117-122 | [Share](#)

THERMAL DEGRADATION KINETICS OF KAEMPFEROL AND QUERCETIN IN THE PRE-FORMULATED OF THE STANDARDIZED EXTRACTS OF POINCIANELLA PYRAMIDALIS (TUL.) L. P. QUEIROZ OBTAINED BY SPRAY DRYER

Agna HÉlia De Oliveira, Renata Da Silva Leite, Fabrício Havy Dantas, Valmir Gomes De Souza, José VenÂncio Chaves Júnior, Fábio Santos De Souza, Rui Oliveira Macedo

[Abstract](#) || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.16935

Pages: 123-128 | [Share](#)

COMMUNITY PHARMACIST-LED NEW MEDICINE SERVICE FOR PATIENTS WITH A LONG TERM MEDICAL CONDITION: A CROSS-SECTIONAL STUDY

Ejaz Cheema, Paul Sutcliffe, Donald Rj Singer

[Abstract](#) || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.17464

Pages: 129-133 | [Share](#)

POTENTIAL DRUG INTERACTIONS IN HYPERTENSIVE PATIENTS IN LIWA DISTRICT HOSPITAL, LAMPUNG BARAT, INDONESIA

Erna Yanti, Erna - Kristin, Alfi Yasmina

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.18003Pages: 134-138 | [Share](#)**TO STUDY THE THERAPEUTIC MANAGEMENT, DRUG RELATED PROBLEMS AND CONCOMITANT USE OF DRUGS IN PATIENTS WITH CANCER**

Pramila P., Anju Abraham, Sunita Pawar, Vibha Bafna, Monika S Bansal

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.18207Pages: 139-144 | [Share](#)**ANTI-INFLAMMATORY ACTIVITY OF CURCUMIN AND CAPSAICIN AUGMENTED IN COMBINATION**

Thriveni Vasanth Kumar, Manjunatha H., Rajesh Kp

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.18635Pages: 145-149 | [Share](#)**LIPID PROFILE PATTERNS AND ASSOCIATION BETWEEN GLYCATED HAEMOGLOBIN (HBA1C) AND ATHEROGENIC INDEX OF PLASMA (AIP) IN DIABETES PATIENTS AT A TERTIARY CARE HOSPITAL IN MALAYSIA**

Mubashra Butt, Adliah Mhd Ali, Mohd Makmor Bakry

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.18639Pages: 150-154 | [Share](#)**COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE IN THE TREATMENT OF METASTATIC BREAST CANCER**

Gabriela Bittencourt Gonzalez Mosegui, Cid Manso De Mello Vianna, Marcus Paulo Da Silva Rodrigues, Talita Martins Alves Da Costa, Paula Medeiros Do Valle

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.18741Pages: 155-160 | [Share](#)**NON-DESTRUCTIVE RAMAN SPECTROSCOPIC METHOD FOR ESTIMATION OF MONTELUKAST FROM TABLET DOSAGES FORM**

Jwal Doctor, Palak Thakkar, Mitul Prajapati, Nrupresh Patel, Priti J. Mehta

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.14043Pages: 161-165 | [Share](#)**SYNTHESIS AND CHARACTERIZATION OF A NOVEL MUCOADHESIVE DERIVATIVE OF PSYLLIUM SEED POLYSACCHARIDE**

Monica R.P. Rao, Snehal R. Gaikwad, Prachi M. Shevate

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.14221Pages: 166-175 | [Share](#)**SENSORY ANALYSIS: THE ATTRIBUTES OF PACKAGING AND PHARMACEUTICAL FORMS OF NAIL STRENGTHENERS COMMERCIALIZED IN BRAZIL**

Jhordana De Oliveira Silva, Lilian De Abreu Ferreira

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.15491Pages: 176-179 | [Share](#)**DESIGN, SYNTHESIS AND ANTICONVULSANT PROFILE OF 5-(BENZO [D][1,3]DIOXOL-5-YL)-3-TERT-BUTYL-4, 5-DIHYDROPIRAZOLE DERIVATIVES**

Mohammed Farrag El-Behairy, Hanan Naeim Hafez Attia

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.17520Pages: 180-188 | [Share](#)**ENHANCED P53-DEPENDENT GROWTH INHIBITION OF HUMAN GLIOBLASTOMA CELLS BY**

COMBINATORIAL TREATMENT OF TEMOZOLOMIDE AND NOVEL PURIFIED NATURAL CARBOHYDRATE OF PLEUROTUS FLORIDA

Priyankar Maji, Ranodeep Chatterjee, Shibani Basu, Biswa P. Choudhury, Urmi Chatterji, Jhuma Ganguly

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.18002Pages: 189-193 | [Share](#)**MANAGING THE EARLY PHASE OF REHABILITATION AFTER ISCHEMIC CEREBROVASCULAR ACCIDENT**

Eqrem Gara, Bekim Haxhiu, Zheralldin Durguti, Ardiana Murtezani

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.18345Pages: 194-197 | [Share](#)**APPLICATION OF THE NEW OROSLIPPERY TECHNOLOGY IN THE PREPARATION OF ENTERIC SLIPPERY COATED TABLET OF NAPROXEN**

Nidhal K. Maraie, Anas T. Alhamdany, Zainab H, Mahdi

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.18676Pages: 198-204 | [Share](#)**STUDY ON IMPLICATIONS OF COPY NUMBER VARIATIONS (CNVS) IN HUMAN POPULATION**

Anushka Yadav, Pooja Singh, Priya Ranjan Kumar, Sarika Srivastava, Santosh Kumar Mishra

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.19029Pages: 205-210 | [Share](#)**Short Communication(s)****BIOACTIVITIES OF THE ETHYL ACETATE EXTRACT OF RHODOCOCCUS QINGSHENGII STRAIN BJC15-A38 AN ENDOPHYTE OF AZADIRACHTA INDICA A. JUSS**

Preeti Saini, Madhurama Gangwar, Amrinder Kaur

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.14389Pages: 211-214 | [Share](#)**Innopharm 2 Conference Proceeding****BLOOD PRESSURE PROFILES AMONG EAST BONGAS AND WEST BONGAS PEOPLE IN EFFORT AND SUPPORT FROM UNIVERSITAS PADJADJARAN AND THE REGENT OF MAJALENGKA REGENCY AND CHIEVES OF THE VILLAGES**

Diah Dhianawaty D., Henhen Heryaman, Mas Rizky Anggun Adipurna Syamsunarno

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.16675Pages: 215-219 | [Share](#)**DESIGN, FORMULATION AND IN VITRO DRUG RELEASE FROM TRANSDERMAL PATCHES CONTAINING IMPRAMINE HYDROCHLORIDE AS MODEL DRUG**

Swati Hardainyan, Krishan Kumar, Bankim Chandra Nandy, Richa Saxena

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.16851Pages: 220-225 | [Share](#)**PHYTOCHEMICAL SCREENING, ELEMENTAL AND FUNCTIONAL GROUP ANALYSIS OF VITEX NEGUNDO L. LEAVES**

Sunil Pawar, Vanita Kamble

Abstract || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.18093Pages: 226-230 | [Share](#)**PHYTOCHEMICAL ANALYSIS AND IN VITRO FREE RADICAL SCAVENGING ACTIVITY OF SUCCESSIVE EXTRACTS OF ALYSICARPUS VAGINALIS VAR. NUMMULARIFOLIUS (DC.) MIQ**

Susan Kurian, Leenamma Joseph, Josekumar V. S.

[Abstract](#) || [View PDF](#) || [View HTML](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.16814

Pages: 231-234 | [Share](#)


THE ROLE OF CARBON NANOTUBES IN NANOBIO-MEDICINES

Anamika Sahu, Aviral Jain, Arvind Gulbake

[Abstract](#) || [View PDF](#) || [Download PDF](#) || DOI: 10.22159/ijpps.2017v9i6.18522

Pages: 235-251 | [Share](#)

[Our Journals](#) || [Open Access Policy](#) || [Publication Ethics](#)

The publication is licensed under a Creative Commons License (CC BY) . [View Legal Code](#)

Copyright © 2017 All Rights Reserved: **Innovare Academic Sciences** || Powered By **CyberDairy**



Scimago Journal & Country Rank Enter Journal Title, ISSN or Publisher Name

Home Journal Rankings Country Rankings Viz Tools Help About Us

International Journal of Pharmacy and Pharmaceutical Sciences

Country [India](#) -  SIR Ranking of India

33

H Index

Subject Area and Category [Pharmacology, Toxicology and Pharmaceutics](#)
[Pharmaceutical Science](#)
[Pharmacology](#)

Publisher [International Journal of Pharmacy and Pharmaceutical Sciences](#)


Publication type Journals

ISSN 09751491


Coverage 2009-2016 (cancelled)

 [Join the conversation about this journal](#)

Quartiles




SJR



Citations per document


Total Cites Self-Cites 




External Cites per Doc Cites per Doc +





% International Collaboration +



Citable documents Non-citable documents +



Cited documents Uncited documents +



International Journal of Pharmacy and...

Q3 Pharmaceutical Science
SJR 2017 0.22
best quartile
powered by scimagojr.com

← Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimaç
```

Ika Puspita Sari 2 months ago

I did published my paper in this journal (vol 8 No. 12 year 2016). What does cancelled coverage means relating to my paper?

Thanks.

reply



Elena Corera 2 months ago

Dear Ika,

Thank you very much for your participation. Our data comes from Scopus/Elsevier, which offers an annual copy of their database. We understand that since the date indicated by Scopus/Elsevier the journal is no longer indexed in its database. While the citation window is still active, we can show indicators of the journal.

Best Regards,
SCImago Team

K

karim bungah 3 months ago

Is this journal scopus indexed?

reply



Elena Corera 3 months ago

Dear Karim,

Thank you very much for your participation. Our data comes from Scopus/Elsevier, which offers an annual copy of their database. We understand that since the date indicated (2016) by Scopus/Elsevier the journal is no longer indexed in its database. While the citation window is still active, we can show indicators of the journal.

Best Regards,
SCImago Team

T

Trideva Sastri 4 months ago

What does cancelled indicate

reply

Leave a comment

Name

Email

(will not be published)

I'm not a robot reCAPTCHA
Privacy - Terms

Submit

The users of Scimago Journal & Country Rank have the possibility to dialogue through comments linked to a specific journal. The purpose is to have a forum in which general doubts about the processes of publication in the journal, experiences and other issues derived from the publication of papers are resolved. For topics on particular articles, maintain the dialogue through the usual channels with your editor.

Developed by:



Powered by:



Follow us on @ScimagoJR

Scimago Lab, Copyright 2007-2018. Data Source: Scopus®

